Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?

Pharmacol Res. 2020 Sep:159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.

Authors

Ying Huang¹, Changming Xie¹, Xiaoke Chen², Qianhui Hong³, Hui Huang⁴

Affiliations

¹ Cardiovascular Department, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518000, China.
² Respiratory Department, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518000, China.
³ Shenzhen Foreign Language School, Shenzhen, 518000, China.
⁴ Cardiovascular Department, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518000, China. Electronic address: huanghui765@hotmail.com.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use*
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / complications
Coronavirus Infections / drug therapy*
Coronavirus Infections / physiopathology
Humans
Hypertension / complications
Hypertension / drug therapy
Hypertension / physiopathology
Pandemics
Peptidyl-Dipeptidase A / physiology
Pneumonia, Viral / complications
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / physiopathology
Receptors, Virus / physiology
Renin-Angiotensin System / drug effects
Renin-Angiotensin System / physiology
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Receptors, Virus
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2